JNCCN study sheds light on multi-organ adverse events from immunotherapy

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A study published in the Journal of the National Comprehensive Cancer Network adds important knowledge about how immunotherapy-related adverse events can impact more than one organ in a single patient.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe

YOU MAY BE INTERESTED IN

When conducting a randomized clinical trial of a treatment regimen based on an immune checkpoint inhibitor, trial sponsors should include overall survival as an endpoint, FDA officials say.

Login